Xifaxan 550 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26F5VFR
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,791
Award facts
- Contract value 100% obligated
- $20,790.71 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
On January 14, 2026, the Defense Logistics Agency awarded a delivery order valued at $20,790.71 to AmerisourceBergen Drug Corp for the supply of XIFAXAN 550 mg tablets (60-count units). This firm fixed-price contract, with an ultimate completion date of January 15, 2026, represents a direct purchase order with no set-aside designation, awarded through open competition. The contract is performed at AmerisourceBergen Drug Corp's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's parent company, Cencora, Inc., which holds a substantial Indefinite Delivery Contract with the DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2031, serving as the primary procurement vehicle for pharmaceutical and medical supplies supporting military healthcare programs globally.
AmerisourceBergen, through Cencora, Inc., functions as a critical pharmaceutical distributor for federal medical procurement needs, particularly supporting military and veteran healthcare systems. The company's portfolio encompasses a comprehensive range of pharmaceutical products including brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. XIFAXAN, an antibiotic medication, aligns with the company's established federal contract history of delivering specialized pharmaceutical commodities to support Defense Health Agency requirements and broader military medical operations. The short completion timeline reflects the urgent nature of pharmaceutical supply chain delivery orders typically processed through the DLA medical supply chain to ensure continuous availability of essential medications for military treatment facilities.
Quick answers
Who was awarded contract SPE2DR26F5VFR?
SPE2DR26F5VFR was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26F5VFR worth?
The government has obligated $20,791 on SPE2DR26F5VFR.
Is contract SPE2DR26F5VFR an order under another contract?
Yes. SPE2DR26F5VFR is a delivery order under SPE2DR25D2105, an indefinite delivery contract.
Was contract SPE2DR26F5VFR competed?
The extent of competition for SPE2DR26F5VFR was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award